{"filing":{"accession_number":"0001193125-26-297992","cik":"0001501796","ticker":"AURA","company_name":"Aura Biosciences, Inc.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"aura-20260703.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526297992/aura-20260703.htm"},"events":[{"id":16598,"run_id":14830,"accession_number":"0001193125-26-297992","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Jeremy Bender, Ph.D., M.B.A., as a Class II director to Aura Biosciences' Board, effective July 7, 2026. The Board unanimously appointed Dr. Bender to fill a newly created vacancy and assigned him to the Compensation Committee and Nominating and Corporate Governance Committee. This is a clear executive appointment event under Item 5.02, with material significance given Dr. Bender's substantial biotechnology leadership experience and the company's advancement toward regulatory approval of its lead candidate bel-sar.","company_name":"Aura Biosciences, Inc.","ticker":"AURA","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14750,"accession_number":"0001193125-26-297992","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Jeremy Bender, Ph.D., M.B.A., as a Class II director to Aura Biosciences' Board, effective July 7, 2026. The Board unanimously appointed Dr. Bender to fill a newly created vacancy and assigned him to the Compensation Committee and Nominating and Corporate Governance Committee. This is a clear executive appointment event under Item 5.02, with material significance given Dr. Bender's substantial biotechnology leadership experience and the company's advancement toward regulatory approval of its lead candidate bel-sar.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:18:47.000347+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14750,"accession_number":"0001193125-26-297992","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Jeremy Bender, Ph.D., M.B.A., as a Class II director to Aura Biosciences' Board, effective July 7, 2026. The Board unanimously appointed Dr. Bender to fill a newly created vacancy and assigned him to the Compensation Committee and Nominating and Corporate Governance Committee. This is a clear executive appointment event under Item 5.02, with material significance given Dr. Bender's substantial biotechnology leadership experience and the company's advancement toward regulatory approval of its lead candidate bel-sar.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:18:47.000347+00:00","company_name":"Aura Biosciences, Inc.","ticker":"AURA","filing_date":"2026-07-08"}]}